DESCRIPTION 

Salbutamol and Beclometasone Dipropionate Pressurised Inhalation is a combination of salbutamol sulphate and beclometasone dipropionate, which have different modes of action and show additive effects. The combination of salbutamol sulphate and beclometasone dipropionate is specially provided for those patients who require regular doses of both drugs for treatment of their obstructive airways disease. 

PHARMACOLOGICAL ACTION 

►Salbutamol sulphate In vitro studies and in vivo pharmacologic studies have demonstrated that salbutamol has a preferential effect on beta2-adrenergic receptors compared with isoproterenol. Although beta2-adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-adrenoceptors are the predominant receptors in the heart, there are also beta2-adrenoceptors in the human heart comprising 10% to 50% of the total beta-adrenoceptors. The precise function of these receptors has not been established, but their presence raises the possibility that even selective beta2-agonists may have cardiac effects.

►Beclometasone dipropionate Beclometasone dipropionate is a corticosteroid demonstrating potent anti-inflammatory activity. The precise mechanism of corticosteroid action on asthma is not known. Corticosteroids have been shown to have multiple anti-inflammatory effects, inhibiting both inflammatory cells (e.g., mast cells, eosinophils, basophils, lymphocytes, macrophages, and neutrophils) and release of inflammatory mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines). These anti-inflammatory actions of corticosteroids contribute to their efficacy in asthma. Beclometasone dipropionate is a prodrug that is rapid